
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been shown to aid faster recovery of hospitalized patients and reduce supplemental oxygen dependence in clinical trials.
The anti-COVID therapeutic application of 2-DG has been developed by India’s Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defense Research and Development Organization (DRDO; Delhi, India), in collaboration with Dr. Reddy’s Laboratories (DRL; Hyderabad, India). A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID-19 patients. The drug will be of immense benefit to people suffering from COVID-19.
Questions remain on DRDO’s COVID drug
You and Me: Is 2DG the new wonder-drug?